{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:10:56Z","timestamp":1788667856648,"version":"build-2803163510"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Artif Organs"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study investigated the therapeutic effects of Huangqi Jixueteng Decoction (HJD) combined with erythropoietin on iron metabolism in patients with renal anemia undergoing maintenance hemodialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Sixty patients with renal anemia receiving maintenance hemodialysis were randomly assigned to a Control Group (CG) treated with erythropoietin alone and an Observation Group (OG) treated with erythropoietin plus HJD. Changes in anemia-related indicators (red blood cell (RBC) count, hematocrit (HCT), hemoglobin (Hb)), inflammatory markers (tumor necrosis factor-\u03b1 (TNF-\u03b1), C-reactive protein (CRP)), iron metabolism parameters (serum ferritin (SF), serum iron (SI), total iron-binding capacity (TIBC), transferrin saturation (TSAT)), and renal and hepatic function indicators (blood urea nitrogen (BUN), serum creatinine (Scr), alanine transaminase (ALT), aspartate transaminase (AST)) were compared between groups. Adverse drug reactions were also monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Baseline values showed no significant differences between groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Post-treatment, RBC, HCT, and Hb levels increased significantly in both groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05), with greater improvement in the OG (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Inflammatory markers declined in both groups, with CRP and TNF-\u03b1 levels significantly lower in the OG compared with the CG (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Indicators of iron metabolism (SF, SI, TIBC, TSAT) improved significantly in both groups (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05), with superior responses in the OG (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Renal and hepatic function indexes (BUN, Scr, AST) decreased post-treatment in both groups, with lower levels in the OG (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). No significant differences were observed in adverse reactions such as dizziness, headache, or low-grade fever (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The addition of Huangqi Jixueteng Decoction to erythropoietin therapy effectively enhances hematologic parameters, mitigates microinflammation, optimizes iron metabolism, and improves renal function in patients with dialysis-associated renal anemia. This integrative regimen appears safe and well tolerated, offering potential advantages for clinical management of renal anemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03913988261474704","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:24:00Z","timestamp":1788409440000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic effects of Huangqi Jixueteng decoction combined with erythropoietin on iron metabolism in in patients with renal anemia"],"prefix":"10.1177","author":[{"given":"Shanzhai","family":"Wei","sequence":"first","affiliation":[{"name":"Nephropathy Department, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9460-5920","authenticated-orcid":false,"given":"Yilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephropathy Department, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangchun","family":"Xu","sequence":"additional","affiliation":[{"name":"Nephropathy Department, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Wang","sequence":"additional","affiliation":[{"name":"Nephropathy Department, Shuyang Hospital of Traditional Chinese Medicine, Shuyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Charles C Ferris AH. Chronic kidney disease. Prim Care 2020; 47(4): 585\u2013595. https:\/\/doi.org\/10.1016\/j.pop.2020.08.001","DOI":"10.1016\/j.pop.2020.08.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Silverberg DS Wexler D Iaina A et al. Anaemia management in cardio renal disease. J Ren Care 2010; 36(Suppl 1): 86\u201396. https:\/\/doi.org\/10.1111\/j.1755-6686.2010.00164.x","DOI":"10.1111\/j.1755-6686.2010.00164.x"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Batchelor EK Kapitsinou P Pergola PE et al. Iron deficiency in chronic kidney disease: Updates on pathophysiology diagnosis and treatment. J Am Soc Nephrol 2020; 31(3): 456\u2013468. https:\/\/doi.org\/10.1681\/ASN.2019020213","DOI":"10.1681\/ASN.2019020213"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Gafter-Gvili A Schechter A Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol 2019; 142(1): 44\u201350. https:\/\/doi.org\/10.1159\/000496492","DOI":"10.1159\/000496492"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Cases A Egocheaga MI Tranche S et al. Anemia of chronic kidney disease: Protocol of study management and referral to Nephrology. Nefrologia (Engl Ed) 2018; 38(1): 8\u201312. https:\/\/doi.org\/10.1016\/j.nefro.2017.09.004","DOI":"10.1016\/j.nefroe.2018.01.007"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Tomosugi N Koshino Y. Tips for erythropoiesis-stimulating agent treatment of renal anemia. Clin Exp Nephrol 2020; 24(1): 105\u2013106. https:\/\/doi.org\/10.1007\/s10157-019-01791-w","DOI":"10.1007\/s10157-019-01791-w"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Kawahara K Minakuchi J Yokota N et al. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. Nephrology (Carlton) 2015; 20(Suppl 4): 29\u201332. https:\/\/doi.org\/10.1111\/nep.12647","DOI":"10.1111\/nep.12647"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Kragesteen BK Giladi A David E et al. The transcriptional and regulatory identity of erythropoietin producing cells. Nat Med 2023; 29(5): 1191\u20131200. https:\/\/doi.org\/10.1038\/s41591-023-02314-7","DOI":"10.1038\/s41591-023-02314-7"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Ry\u0161av\u00e1 R. Novinky v l\u00e9\u010db\u011b ren\u00e1ln\u00ed an\u00e9mie - erytropoetin vs. inhibitory prolylhydroxyl\u00e1zy? [New developments in anaemia treatment - erythropoietin versus prolyl hydroxylase inhibitors?]. Vnitr Lek 2022; 68(7): 438\u2013443. https:\/\/doi.org\/10.36290\/vnl.2022.092","DOI":"10.36290\/vnl.2022.092"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Locatelli F Paoletti E Del Vecchio L. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review. Expert Opin Drug Saf 2023; 22(12): 1179\u20131191. https:\/\/doi.org\/10.1080\/14740338.2023.2285889","DOI":"10.1080\/14740338.2023.2285889"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Liu H Ye Y Chen Y et al. Therapeutic targets for the anemia of predialysis chronic kidney disease: a meta-analysis of randomized controlled trials. J Investig Med 2019; 67(6): 1002\u20131008. https:\/\/doi.org\/10.1136\/jim-2018-000915","DOI":"10.1136\/jim-2018-000915"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Garrido P Ribeiro S Fernandes J et al. Iron-hepcidin dysmetabolism anemia and renal hypoxia inflammation and fibrosis in the remnant kidney rat model. PLoS One 2015; 10(4): e0124048. https:\/\/doi.org\/10.1371\/journal.pone.0124048","DOI":"10.1371\/journal.pone.0124048"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"D\u00f6mling A Li X. TNF-\u03b1: the shape of small molecules to come? Drug Discov Today 2022; 27(1): 3\u20137. https:\/\/doi.org\/10.1016\/j.drudis.2021.06.018","DOI":"10.1016\/j.drudis.2021.06.018"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Huyghe J Priem D Bertrand MJM. Cell death checkpoints in the TNF pathway. Trends Immunol 2023; 44(8): 628\u2013643. https:\/\/doi.org\/10.1016\/j.it.2023.05.007","DOI":"10.1016\/j.it.2023.05.007"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Matsuoka T Abe M Kobayashi H. Iron Metabolism and Inflammatory Mediators in Patients with Renal Dysfunction. Int J Mol Sci 2024; 25(7): 3745. https:\/\/doi.org\/10.3390\/ijms25073745","DOI":"10.3390\/ijms25073745"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Ogawa C Tsuchiya K Maeda K et al. Renal Anemia and Iron Metabolism. Contrib Nephrol 2018; 195: 62\u201373. https:\/\/doi.org\/10.1159\/000486936","DOI":"10.1159\/000486936"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Garg N Kotru M Yadav A et al. Serum ferritin <70 \u03bcg\/L predicts functional iron deficiency in patients with chronic kidney disease. Saudi J Kidney Dis Transpl 2018; 29(5): 1035\u20131041. https:\/\/doi.org\/10.4103\/1319-2442.243956","DOI":"10.4103\/1319-2442.243956"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Toblli JE Cao G Rivas C et al. Heart and iron deficiency anaemia in rats with renal insufficiency: the role of hepcidin. Nephrology (Carlton) 2008; 13(7): 636\u2013645. https:\/\/doi.org\/10.1111\/j.1440-1797.2008.01019.x","DOI":"10.1111\/j.1440-1797.2008.01019.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Jeli\u0107 M Cvetkovi\u0107 T Djordjevi\u0107 V et al. Hepcidin and iron metabolism disorders in patients with chronic kidney disease. Vojnosanit Pregl 2013; 70(4): 368\u2013373. https:\/\/doi.org\/10.2298\/vsp1304368j","DOI":"10.2298\/VSP1304368J"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Dong M Li J Yang D et al. Biosynthesis and pharmacological activities of flavonoids Triterpene saponins and polysaccharides derived from Astragalus membranaceus. Molecules 2023; 28(13): 5018. https:\/\/doi.org\/10.3390\/molecules28135018","DOI":"10.3390\/molecules28135018"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Jin M Zhao K Huang Q et al. Structural features and biological activities of the polysaccharides from Astragalus membranaceus. Int J Biol Macromol 2014; 64: 257\u2013266. https:\/\/doi.org\/10.1016\/j.ijbiomac.2013.12.002","DOI":"10.1016\/j.ijbiomac.2013.12.002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Dong XZ Wang YN Tan X et al. Protective effect of JXT ethanol extract on radiation-induced hematopoietic alteration and oxidative stress in the liver. Oxid Med Cell Longev 2018; 2018: 9017835. https:\/\/doi.org\/10.1155\/2018\/9017835","DOI":"10.1155\/2018\/9017835"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Guan Y An P Zhang Z et al. Screening identifies the Chinese medicinal plant Caulis Spatholobi as an effective HAMP expression inhibitor. J Nutr 2013; 143(7): 1061\u20131066. https:\/\/doi.org\/10.3945\/jn.113.174201","DOI":"10.3945\/jn.113.174201"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Guo M Zeng J Li W et al. Danggui Jixueteng decoction for the treatment of myelosuppression after chemotherapy: a combined metabolomics and network pharmacology analysis. Heliyon 2024; 10(3): e24695. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24695","DOI":"10.1016\/j.heliyon.2024.e24695"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Liu Y Dai S Xu Y et al. Integration of network pharmacology and experimental validation to explore Jixueteng - Yinyanghuo herb pair alleviate cisplatin-induced myelosuppression. Integr Cancer Ther 2024; 23: 15347354241237969. https:\/\/doi.org\/10.1177\/15347354241237969","DOI":"10.1177\/15347354241237969"}],"container-title":["The International Journal of Artificial Organs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03913988261474704","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03913988261474704","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03913988261474704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:38:09Z","timestamp":1788665889000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03913988261474704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":25,"alternative-id":["10.1177\/03913988261474704"],"URL":"https:\/\/doi.org\/10.1177\/03913988261474704","relation":{},"ISSN":["0391-3988","1724-6040"],"issn-type":[{"value":"0391-3988","type":"print"},{"value":"1724-6040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"article-number":"03913988261474704"}}